VB vs XBI
Vanguard Small-Cap ETF vs SPDR S&P Biotech ETF
- • VB has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • VB pays a higher dividend yield (1.23%).
Side-by-side metrics
| Metric | VB | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.23% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $177.42B | $8.30B |
YTD return | 13.19% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.16 | 1.09 |
P/E ratio | 22.28 | — |
Last price | $286.58 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VB top holdings
| EME | EMCOR Group Inc | 0.46% |
| NRG | NRG Energy Inc | 0.43% |
| ATO | Atmos Energy Corp | 0.42% |
| TPR | Tapestry Inc | 0.40% |
| FTI | TechnipFMC PLC | 0.38% |
| CIEN | Ciena Corp | 0.38% |
| CASY | Casey's General Stores Inc | 0.37% |
| JBL | Jabil Inc | 0.37% |
| NTRA | Natera Inc | 0.37% |
| EXE | Expand Energy Corp Ordinary Shares - New | 0.37% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VB
VB (Vanguard Small-Cap ETF) is US small-cap stocks across sectors. Managed by Vanguard, the fund carries $177.4B in assets under management, an expense ratio of 0.03%, a dividend yield of 1.23%. Its largest holding is EMCOR Group Inc (EME), which represents 0.5% of the portfolio. Real Estate is the fund's largest sector exposure at 7.7%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.